Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH Analogues vs Mifepristone After TCRM for Residual Fibroids
NCT05898321Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of goserelin and mifepristone in uterine leiomyoma (3 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: remaining submucous fibroids volume. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
goserelinmifepristone
03
Conditions
uterine leiomyoma
Beyond the preview
Go deeper on NCT05898321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898321.